GSK/Pozen Trexima update
This article was originally published in Pharmaceutical Approvals Monthly
Pozen plans to submit an NDA in the third quarter for its migraine combination therapy Trexima (sumatriptan/naproxen) following a pre-NDA meeting with FDA. The firm also announced that Trexima showed statistically significant results for all primary endpoints in a second pivotal trial. Based on discussion at the pre-NDA meeting, Pozen "believes that no additional preclinical or clinical trials are necessary for submission," the firm says April 21. In the pivotal trial, Trexima showed superiority over its individual components with respect to pain-free response and pain relief. At the moment, Trexima appears to be Pozen's most promising product. The firm's other migraine agents, MT-100 and MT-300, are both "not approvable" at FDA. The agency recently postponed an MT-100 advisory committee...
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
A study with nearly 500 patients with vitamin D levels tested within a year before receiving COVID-19 tests found subjects deficient in the nutrient had 1.77 greater chance of testing positive. Researchers say RCTs are needed to determine if broad population interventions are necessary.
The company is running a pilot program to allow glioblastoma patients who use Novocure’s Optune Tumor Treating Fields device to download data from the device at home.